The most important takeaway from the study is that these data suggest that CD47 is an attractive target for drug development.

A new study from the USC Norris Comprehensive Cancer Center has found evidence that targeting CD47, a protein that is part of ...

你是否曾经好奇过，科学家们是如何在抗癌的道路上不断取得突破的？近日，一项具有里程碑意义的临床研究在全球范围内引起了广泛关注。康方生物宣布其自主研发的PD-1/VEGF双特异性抗体依沃西联合新一代CD47单抗莱法利，对比帕博利珠单抗一线治疗PD-L1阳性复发转移性头颈部鳞癌（R/MHNSCC）的III期临床研究完成首例患者入组。这标志着全球首个CD47单抗疗法治疗实体瘤的Ⅲ期临床研究正式启动。

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on STTK stock, giving a Hold rating today. Joseph Pantginis has ...

Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

2024 年肿瘤免疫治疗学会年会（SITC 2024）于 11 月 6 日-10 日在美国休斯敦召开，康方生物在该会议上首次对外发布了其独立自主研发的双特异性抗体新药 Claudin18.2(CLDN18.2)/CD47 AK132 ...

A new study from the USC Norris Comprehensive Cancer Center has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal ...

HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. AK132 is an asymmetric bispecific ...

HK) presented the mechanism of action (MOA) research findings of its innovative bispecific antibody, AK132, targeting both Claudin18.2 (CLDN18.2) and CD47. AK132 is an asymmetric bispecific antibody ...